SEITZ-HOLLAND, Johanna, Magdalena SEETHALER, Nikos MAKRIS, Jarrett RUSHMORE, Kang-Ik K. CHO, Elizabeth RIZZONI, Mark VANGEL, Olcay Senay SAHIN, Carina HELLER, Ofer PASTERNAK, Filip SZCZEPANKIEWICZ, Carl-Fredrik WESTIN, Jan LOŠÁK, Libor USTOHAL, Josef TOMANDL, Lubomír VOJTÍŠEK, Petr KUDLIČKA, Martin JÁNI, T. Wilson WOO, Tomáš KAŠPÁREK, Zora KIKINIS and Marek KUBICKI. The association of matrix metalloproteinase 9 (MMP9) with hippocampal volume in schizophrenia: a preliminary MRI study. Neuropsychopharmacology. London: Springer-Nature, 2022, vol. 47, No 2, p. 524-530. ISSN 0893-133X. Available from: https://dx.doi.org/10.1038/s41386-021-00997-5.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name The association of matrix metalloproteinase 9 (MMP9) with hippocampal volume in schizophrenia: a preliminary MRI study
Authors SEITZ-HOLLAND, Johanna, Magdalena SEETHALER, Nikos MAKRIS, Jarrett RUSHMORE, Kang-Ik K. CHO, Elizabeth RIZZONI, Mark VANGEL, Olcay Senay SAHIN, Carina HELLER, Ofer PASTERNAK, Filip SZCZEPANKIEWICZ, Carl-Fredrik WESTIN, Jan LOŠÁK (203 Czech Republic, belonging to the institution), Libor USTOHAL (203 Czech Republic, belonging to the institution), Josef TOMANDL (203 Czech Republic, belonging to the institution), Lubomír VOJTÍŠEK (203 Czech Republic, belonging to the institution), Petr KUDLIČKA (203 Czech Republic, belonging to the institution), Martin JÁNI (703 Slovakia, belonging to the institution), T. Wilson WOO, Tomáš KAŠPÁREK (203 Czech Republic, belonging to the institution), Zora KIKINIS and Marek KUBICKI.
Edition Neuropsychopharmacology, London, Springer-Nature, 2022, 0893-133X.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30215 Psychiatry
Country of publisher United Kingdom of Great Britain and Northern Ireland
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 7.600
RIV identification code RIV/00216224:14110/22:00124919
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1038/s41386-021-00997-5
UT WoS 000638047300004
Keywords in English matrix metalloproteinase 9 (MMP9); hippocampal volume; schizophrenia
Tags 14110127, 14110222, 14110512, CF MAFIL, podil, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 1/2/2022 11:27.
Abstract
Matrix metalloproteinases 9 (MMP9) are enzymes involved in regulating neuroplasticity in the hippocampus. This, combined with evidence for disrupted hippocampal structure and function in schizophrenia, has prompted our current investigation into the relationship between MMP9 and hippocampal volumes in schizophrenia. 34 healthy individuals (mean age = 32.50, male = 21, female = 13) and 30 subjects with schizophrenia (mean age = 33.07, male = 19, female = 11) underwent a blood draw and T1-weighted magnetic resonance imaging. The hippocampus was automatically segmented utilizing FreeSurfer. MMP9 plasma levels were measured with ELISA. ANCOVAs were conducted to compare MMP9 plasma levels (corrected for age and sex) and hippocampal volumes between groups (corrected for age, sex, total intracranial volume). Spearman correlations were utilized to investigate the relationship between symptoms, medication, duration of illness, number of episodes, and MMP9 plasma levels in patients. Last, we explored the correlation between MMP9 levels and hippocampal volumes in patients and healthy individuals separately. Patients displayed higher MMP9 plasma levels than healthy individuals (F(1, 60) = 21.19, p < 0.0001). MMP9 levels correlated with negative symptoms in patients (R = 0.39, p = 0.035), but not with medication, duration of illness, or the number of episodes. Further, patients had smaller left (F(1,59) = 9.12, p = 0.0040) and right (F(1,59) = 6.49, p = 0.013) hippocampal volumes. Finally, left (R = -0.39, p = 0.034) and right (R = -0.37, p = 0.046) hippocampal volumes correlated negatively with MMP9 plasma levels in patients. We observe higher MMP9 plasma levels in SCZ, associated with lower hippocampal volumes, suggesting involvement of MMP9 in the pathology of SCZ. Future studies are needed to investigate how MMP9 influences the pathology of SCZ over the lifespan, whether the observed associations are specific for schizophrenia, and if a therapeutic modulation of MMP9 promotes neuroprotective effects in SCZ.
Links
LM2018129, research and development projectName: Národní infrastruktura pro biologické a medicínské zobrazování Czech-BioImaging
Investor: Ministry of Education, Youth and Sports of the CR
PrintDisplayed: 27/4/2024 00:21